Sarepta Therapeutics Inc (SRPT)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$36.21

Buy

$36.65

arrow-down$-0.17 (-0.47%)

Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.
Prices updated at 14 May 2025, 00:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up1.61%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
-
CEO
Mr. Douglas S. Ingram,Esq.
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,372
Head office
215 First Street
Cambridge
United States
02142
mobile
+1 617 274-4000
letter
iestepan@sarepta.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Ms. Deirdre P. Connelly
Independent Director
0.02m--0.73m-
Mr. Douglas S. Ingram,Esq.
Director, President and Chief Executive Officer
0.85m--1.98m-
Dr. M. Kathleen Behrens Wilsey, PhD
Chairwoman of the Board
0.13m--0.62m-
Dr. Claude Nicaise,M.D.
Independent Director
0.08m--0.56m-
Dr. Hans Wigzell, M.D.,PhD
Independent Director
0.09m--0.57m-
Mr. Richard J. Barry
Independent Director
0.11m--0.59m-
Dr. Kathryn Jean Boor, PhD
Independent Director
0.08m--0.56m-
Ms. Louise Rodino-Klapac
Executive Vice President, Head of R&D and Chief Scientific Officer
0.67m--2.74m-
Mr. Ian Michael Estepan
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
0.66m--2.75m-
Dr. Stephen L. Mayo, PhD
Independent Director
0.08m--0.57m-
Mr. Michael A. Chambers
Independent Director
0.07m--0.55m-
Mr. Bilal Arif
Executive Vice President and Chief Technical Operations Officer
0.55m--2.54m-
Mr. Dallan Murray
Executive Vice President and Chief Customer Officer
0.62m--2.67m-
Mr. Cristin Rothfuss
Executive Vice President, Chief General Counsel and Corporate Secretary
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
BlackRock Inc11,191,9860.027541686721.53013930 Apr 202511.39
Vanguard Group Inc9,085,4560.019241179041.31478530 Apr 20259.25
Capital Research & Mgmt Co - Division 38,697,1370.19866243785538.94783830 Apr 20258.85
Capital Research and Management Company8,449,9321.3678969067-30 Apr 20258.60
Capital Group8,130,0050.91918228437-30 Apr 20258.27

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
27 Dec 2024-Mr. Ian Michael Estepan--33,696--
12 Dec 2024-Dr. Hans Wigzell, M.D.,PhD-----
12 Dec 2024-Dr. Hans Wigzell, M.D.,PhD124.841,310,82022,840--
12 Dec 2024-Dr. Hans Wigzell, M.D.,PhD13.71143,95533,340--
05 Dec 2024-Dr. Kathryn Jean Boor, PhD125.55205,4005,880--
26 Nov 2024-Mr. Cristin Rothfuss--13,817--
26 Nov 2024-Mr. Cristin Rothfuss--4,000--
18 Nov 2024-Ms. Louise Rodino-Klapac102.89468,97367,630--
12 Sep 2024-Ms. Deirdre P. Connelly--6,442--
12 Sep 2024-Ms. Deirdre P. Connelly--2,842--
04 Sep 2024-Dr. M. Kathleen Behrens Wilsey, PhD--191,093--
30 Aug 2024-Mr. Ian Michael Estepan137.36822,10033,946--
16 Aug 2024-Mr. Michael Chambers134.062,451,153278,386--
16 Aug 2024-Mr. Michael Chambers134.66760,560284,034--
16 Aug 2024-Mr. Michael Chambers133.071,744,015260,102--
03 Jul 2024-Dr. M. Kathleen Behrens Wilsey, PhD13.90208,500191,839--
03 Jul 2024-Dr. M. Kathleen Behrens Wilsey, PhD-----
21 Jun 2024-Ms. Louise Rodino-Klapac--5,500--
21 Jun 2024-Ms. Louise Rodino-Klapac--6,250--
21 Jun 2024-Ms. Louise Rodino-Klapac-----
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.